CN1634311A - Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis - Google Patents

Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis Download PDF

Info

Publication number
CN1634311A
CN1634311A CN 200410060534 CN200410060534A CN1634311A CN 1634311 A CN1634311 A CN 1634311A CN 200410060534 CN200410060534 CN 200410060534 CN 200410060534 A CN200410060534 A CN 200410060534A CN 1634311 A CN1634311 A CN 1634311A
Authority
CN
China
Prior art keywords
rhizoma
radix
fructus
parched
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200410060534
Other languages
Chinese (zh)
Other versions
CN1261149C (en
Inventor
陈玉兰
杨琰
梁汉章
杨洋
Original Assignee
陈玉兰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陈玉兰 filed Critical 陈玉兰
Priority to CN 200410060534 priority Critical patent/CN1261149C/en
Publication of CN1634311A publication Critical patent/CN1634311A/en
Application granted granted Critical
Publication of CN1261149C publication Critical patent/CN1261149C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis wherein the medicine mainly comprises (by weight ratio) astragalus root, magnolia obavata, chicken's gizzard-skin, malt, amomum fruit, dried orange peel, medicated leaven, radix adenophorae, Chinese angelica root, Ligusticum wallichii, Poria cocos, bitter orange, atractylodes rhizome, white atractylodes rhizome, job's tears, large-leaf gentian root, Japanese yam, ledebouriella root, rhizoma corydalis, common fennel fruit, Chinese honeylocust spine, oyster shell, drynaria, buck grass, Bupleurum root, cimicifuga rhizome.

Description

The medicine of treatment rheumatoid arthritis, femur head necrosis, ankylosing spondylitis
Technical field
The present invention relates to a kind of Chinese medicine, especially relate to a kind of medicine for the treatment of rheumatoid arthritis, femur head necrosis, ankylosing spondylitis.
Background technology
Generally all adopt high antiinflammatory, high analgesic medicine, cooperate injection anesthesia needle, hormonal medicaments to treat for diseases such as rheumatoid arthritis, femur head necrosis, ankylosing spondylitises at present.From present therapeutic outcome, control disease often and do not cure the disease, only play the effect of relief of symptoms, and sclerotin is still in pathological changes, therapeutic effect is undesirable, has often incured loss through delay the state of an illness, finally causes adopting operating Therapeutic Method, causes patient maimed person.
Summary of the invention
The objective of the invention is provides a kind of medicine for the treatment of rheumatoid arthritis, femur head necrosis, ankylosing spondylitis at above-mentioned existing in prior technology deficiency.
For achieving the above object, the present invention can take following technical proposals:
The medicine of treatment rheumatoid arthritis of the present invention, femur head necrosis, ankylosing spondylitis, it is combined by following proportioning raw materials (weight portion) substantially:
Radix Astragali 18-20, Cortex Magnoliae Officinalis 6-15, Endothelium Corneum Gigeriae Galli 15-20, Fructus Hordei Germinatus (parched) 15-30, Fructus Amomi 6-15, Pericarpium Citri Reticulatae 6-15, Massa Medicata Fermentata 15-20, RADIX GLEHNIAE from Liaoning of China 20-30, Radix Angelicae Sinensis 8-15, Rhizoma Chuanxiong 8-15, Poria 12-15, Fructus Aurantii (parched) 10-15, Rhizoma Atractylodis 6-10, Rhizoma Atractylodis Macrocephalae 10-18, Semen Coicis 18-30, Radix Gentianae Macrophyllae 6-10, Rhizoma Dioscoreae Nipponicae 6-10, Radix Saposhnikoviae 6-15, Rhizoma Corydalis 6-20, Fructus Foeniculi 8-15, Squama Manis 10-15, Spina Gleditsiae 6-10, Concha Ostreae 15-30, Rhizoma Drynariae 12-15, Herba Lycopodii 6-10, Radix Bupleuri 6-10, Rhizoma Cimicifugae 3-6, cattle sunset 8-12.
Medicine of the present invention can combine by following proportioning raw materials (weight portion):
The Radix Astragali 18, Cortex Magnoliae Officinalis 6, Endothelium Corneum Gigeriae Galli 15, Fructus Hordei Germinatus (parched) 15, Fructus Amomi 6, Pericarpium Citri Reticulatae 6, Massa Medicata Fermentata 15, RADIX GLEHNIAE from Liaoning of China 20, Radix Angelicae Sinensis 8, Rhizoma Chuanxiong 8, Poria 12, Fructus Aurantii (parched) 10, Rhizoma Atractylodis 6, the Rhizoma Atractylodis Macrocephalae 10, Semen Coicis 18, Radix Gentianae Macrophyllae 6, Rhizoma Dioscoreae Nipponicae 6, Radix Saposhnikoviae 6, Rhizoma Corydalis 6, Fructus Foeniculi 8, Squama Manis 10, Spina Gleditsiae 60, Concha Ostreae 15, Rhizoma Drynariae 12, Herba Lycopodii 6, Radix Bupleuri 6, Rhizoma Cimicifugae 3, cattle sunset 8.
Medicine of the present invention also can combine by following proportioning raw materials (weight portion):
The Radix Astragali 19, Cortex Magnoliae Officinalis 11, Endothelium Corneum Gigeriae Galli 18, Fructus Hordei Germinatus (parched) 22, Fructus Amomi 9, Pericarpium Citri Reticulatae 10, Massa Medicata Fermentata 18, RADIX GLEHNIAE from Liaoning of China 25, Radix Angelicae Sinensis 11, Rhizoma Chuanxiong 12, Poria 14, Fructus Aurantii (parched) 13, Rhizoma Atractylodis 8, the Rhizoma Atractylodis Macrocephalae 15, Semen Coicis 25, Radix Gentianae Macrophyllae 8, Rhizoma Dioscoreae Nipponicae 7, Radix Saposhnikoviae 12, Rhizoma Corydalis 12, Fructus Foeniculi 11, Squama Manis 13, Spina Gleditsiae 8, Concha Ostreae 23, Rhizoma Drynariae 13, Herba Lycopodii 8, Radix Bupleuri 8, Rhizoma Cimicifugae 5, cattle sunset 10.
Medicine of the present invention also can combine by following proportioning raw materials (weight portion):
The Radix Astragali 20, Cortex Magnoliae Officinalis 15, Endothelium Corneum Gigeriae Galli 20, Fructus Hordei Germinatus (parched) 30, Fructus Amomi 15, Pericarpium Citri Reticulatae 15, Massa Medicata Fermentata 20, RADIX GLEHNIAE from Liaoning of China 30, Radix Angelicae Sinensis 15, Rhizoma Chuanxiong 15, Poria 15, Fructus Aurantii (parched) 15, Rhizoma Atractylodis 10, the Rhizoma Atractylodis Macrocephalae 18, Semen Coicis 30, Radix Gentianae Macrophyllae 10, Rhizoma Dioscoreae Nipponicae 10, Radix Saposhnikoviae 15, Rhizoma Corydalis 20, Fructus Foeniculi 15, Squama Manis 15, Spina Gleditsiae 10, Concha Ostreae 30, Rhizoma Drynariae 15, Herba Lycopodii 10, Radix Bupleuri 10, Rhizoma Cimicifugae 6, cattle sunset 12.
The invention has the advantages that relief of symptoms, suppress the state of an illness, improve patient immune function, metabolic function and internal organs function, do not recur purpose to reach healing.Adopt this treatment by Chinese herbs to need not to take anti-inflammation analgesis medicament, drawing liquid is not done repairing operation.With first, the different state of an illness of intermediary and later stages, general through individual month the function that can recover the patient course of treatment of 1-5, when enhance immunity, balance metabolism, removing wind-damp dispelling, Repercusion analgesia, the high erythrocyte sedimentation rate of change rheumatoid arthritis that can be stable, the positive factor of rheumatoid, lupus erythematosus cell (LE cell), goat hyperuricemia suppress, get rid of goat.Medicine of the present invention is a decoction, also can make electuary, pill according to a conventional method.
Chinese medicine clinical treatment statistics case of the present invention sees the following form:
Figure A20041006053400041
Rheumatoid arthritis:
The treatment number: 375 people, wherein: man, 203 people; The woman, 172 people.
Patient age: 10-20 year, 145 people; 20-40 year, 161 people; More than 40 years old, 69 people.
Medical history: 1-3,205 people; 3-5,95 people; 5-10,72 people; More than 10 years, 3 people.
Cured 165 people the course of treatment: 1-3 month; 3-5 month, 173 people; More than 5 months, 37 people.
Ischemia femur head necrosis:
Treatment number: 32 people.
Patient age: 10-20 year, 11 people; 20-40 year, 15 people; More than 40 years old, 6 people.
Medical history: 1-3,15 people; 3-5,13 people; 5-10,4 people.
Cured 19 people the course of treatment: 3-5 month; More than 5 months, 13 people.
Ankylosing spondylitis:
Treatment number: 38 people.
Patient age: 10-20 year, 5 people; 20-40 year, 21 people; More than 40 years old, 12 people.
Medical history: 1-3,19 people; 3-5,12 people; 5-10,7 people.
Cured 28 people the course of treatment: 3-5 month; More than 5 months, 10 people.
The specific embodiment
Embodiment 1:
Medicine of the present invention is combined by following proportioning raw materials (weight portion):
The Radix Astragali 18, Cortex Magnoliae Officinalis 6, Endothelium Corneum Gigeriae Galli 15, Fructus Hordei Germinatus (parched) 15, Fructus Amomi 6, Pericarpium Citri Reticulatae 6, Massa Medicata Fermentata 15, RADIX GLEHNIAE from Liaoning of China 20, Radix Angelicae Sinensis 8, Rhizoma Chuanxiong 8, Poria 12, Fructus Aurantii (parched) 10, Rhizoma Atractylodis 6, the Rhizoma Atractylodis Macrocephalae 10, Semen Coicis 18, Radix Gentianae Macrophyllae 6, Rhizoma Dioscoreae Nipponicae 6, Radix Saposhnikoviae 6, Rhizoma Corydalis 6, Fructus Foeniculi 8, Squama Manis 10, Spina Gleditsiae 60, Concha Ostreae 15, Rhizoma Drynariae 12, Herba Lycopodii 6, Radix Bupleuri 6, Rhizoma Cimicifugae 3, cattle sunset 8.
Embodiment 2:
Medicine of the present invention is combined by following proportioning raw materials (weight portion):
The Radix Astragali 19, Cortex Magnoliae Officinalis 11, Endothelium Corneum Gigeriae Galli 18, Fructus Hordei Germinatus (parched) 22, Fructus Amomi 9, Pericarpium Citri Reticulatae 10, Massa Medicata Fermentata 18, RADIX GLEHNIAE from Liaoning of China 25, Radix Angelicae Sinensis 11, Rhizoma Chuanxiong 12, Poria 14, Fructus Aurantii (parched) 13, Rhizoma Atractylodis 8, the Rhizoma Atractylodis Macrocephalae 15, Semen Coicis 25, Radix Gentianae Macrophyllae 8, Rhizoma Dioscoreae Nipponicae 7, Radix Saposhnikoviae 12, Rhizoma Corydalis 12, Fructus Foeniculi 11, Squama Manis 13, Spina Gleditsiae 8, Concha Ostreae 23, Rhizoma Drynariae 13, Herba Lycopodii 8, Radix Bupleuri 8, Rhizoma Cimicifugae 5, cattle sunset 10.
Embodiment 3:
Medicine of the present invention is combined by following proportioning raw materials (weight portion):
The Radix Astragali 20, Cortex Magnoliae Officinalis 15, Endothelium Corneum Gigeriae Galli 20, Fructus Hordei Germinatus (parched) 30, Fructus Amomi 15, Pericarpium Citri Reticulatae 15, Massa Medicata Fermentata 20, RADIX GLEHNIAE from Liaoning of China 30, Radix Angelicae Sinensis 15, Rhizoma Chuanxiong 15, Poria 15, Fructus Aurantii (parched) 15, Rhizoma Atractylodis 10, the Rhizoma Atractylodis Macrocephalae 18, Semen Coicis 30, Radix Gentianae Macrophyllae 10, Rhizoma Dioscoreae Nipponicae 10, Radix Saposhnikoviae 15, Rhizoma Corydalis 20, Fructus Foeniculi 15, Squama Manis 15, Spina Gleditsiae 10, Concha Ostreae 30, Rhizoma Drynariae 15, Herba Lycopodii 10, Radix Bupleuri 10, Rhizoma Cimicifugae 6, cattle sunset 12.

Claims (4)

1, a kind of medicine for the treatment of rheumatoid arthritis, femur head necrosis, ankylosing spondylitis is characterized in that: it is combined by following proportioning raw materials (weight portion) substantially:
Radix Astragali 18-20, Cortex Magnoliae Officinalis 6-15, Endothelium Corneum Gigeriae Galli 15-20, Fructus Hordei Germinatus (parched) 15-30, Fructus Amomi 6-15, Pericarpium Citri Reticulatae
6-15, Massa Medicata Fermentata 15-20, RADIX GLEHNIAE from Liaoning of China 20-30, Radix Angelicae Sinensis 8-15, Rhizoma Chuanxiong 8-15, Poria 12-15, stir-fry
Fructus Aurantii 10-15, Rhizoma Atractylodis 6-10, Rhizoma Atractylodis Macrocephalae 10-18, Semen Coicis 18-30, Radix Gentianae Macrophyllae 6-10, Rhizoma Dioscoreae Nipponicae 6-10,
Radix Saposhnikoviae 6-15, Rhizoma Corydalis 6-20, Fructus Foeniculi 8-15, Squama Manis 10-15, Spina Gleditsiae 6-10, Concha Ostreae 15-30,
Rhizoma Drynariae 12-15, Herba Lycopodii 6-10, Radix Bupleuri 6-10, Rhizoma Cimicifugae 3-6, cattle sunset 8-12.
2, medicine according to claim 1 is characterized in that: it is combined by following proportioning raw materials (weight portion):
The Radix Astragali 18, Cortex Magnoliae Officinalis 6, Endothelium Corneum Gigeriae Galli 15, Fructus Hordei Germinatus (parched) 15, Fructus Amomi 6, Pericarpium Citri Reticulatae 6, Massa Medicata Fermentata 15, the Liao Dynasty's sand
Ginseng 20, Radix Angelicae Sinensis 8, Rhizoma Chuanxiong 8, Poria 12, Fructus Aurantii (parched) 10, Rhizoma Atractylodis 6, the Rhizoma Atractylodis Macrocephalae 10, Semen Coicis 18,
Radix Gentianae Macrophyllae 6, Rhizoma Dioscoreae Nipponicae 6, Radix Saposhnikoviae 6, Rhizoma Corydalis 6, Fructus Foeniculi 8, Squama Manis 10, Spina Gleditsiae 6, Concha Ostreae
15, Rhizoma Drynariae 12, Herba Lycopodii 6, Radix Bupleuri 6, Rhizoma Cimicifugae 3, cattle sunset 8.
3, medicine according to claim 1 is characterized in that: it is combined by following proportioning raw materials (weight portion) substantially:
The Radix Astragali 19, Cortex Magnoliae Officinalis 11, Endothelium Corneum Gigeriae Galli 18, Fructus Hordei Germinatus (parched) 22, Fructus Amomi 9, Pericarpium Citri Reticulatae 10, Massa Medicata Fermentata 18, the Liao Dynasty
Radix Adenophorae (Radix Glehniae) 25, Radix Angelicae Sinensis 11, Rhizoma Chuanxiong 12, Poria 14, Fructus Aurantii (parched) 13, Rhizoma Atractylodis 8, the Rhizoma Atractylodis Macrocephalae 15, Semen Coicis
25, Radix Gentianae Macrophyllae 8, Rhizoma Dioscoreae Nipponicae 7, Radix Saposhnikoviae 12, Rhizoma Corydalis 12, Fructus Foeniculi 11, Squama Manis 13, Spina Gleditsiae 8,
Concha Ostreae 23, Rhizoma Drynariae 13, Herba Lycopodii 8, Radix Bupleuri 8, Rhizoma Cimicifugae 5, cattle sunset 10.
4, medicine according to claim 1 is characterized in that: it is combined by following proportioning raw materials (weight portion) substantially:
The Radix Astragali 20, Cortex Magnoliae Officinalis 15, Endothelium Corneum Gigeriae Galli 20, Fructus Hordei Germinatus (parched) 30, Fructus Amomi 15, Pericarpium Citri Reticulatae 15, Massa Medicata Fermentata 20, the Liao Dynasty
Radix Adenophorae (Radix Glehniae) 30, Radix Angelicae Sinensis 15, Rhizoma Chuanxiong 15, Poria 15, Fructus Aurantii (parched) 15, Rhizoma Atractylodis 10, the Rhizoma Atractylodis Macrocephalae 18, Semen Coicis
30, Radix Gentianae Macrophyllae 10, Rhizoma Dioscoreae Nipponicae 10, Radix Saposhnikoviae 15, Rhizoma Corydalis 20, Fructus Foeniculi 15, Squama Manis 15, Spina Gleditsiae 10,
Concha Ostreae 30, Rhizoma Drynariae 15, Herba Lycopodii 10, Radix Bupleuri 10, Rhizoma Cimicifugae 6, cattle sunset 12.
CN 200410060534 2004-09-23 2004-09-23 Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis Expired - Fee Related CN1261149C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN 200410060534 CN1261149C (en) 2004-09-23 2004-09-23 Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN 200410060534 CN1261149C (en) 2004-09-23 2004-09-23 Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis

Publications (2)

Publication Number Publication Date
CN1634311A true CN1634311A (en) 2005-07-06
CN1261149C CN1261149C (en) 2006-06-28

Family

ID=34846253

Family Applications (1)

Application Number Title Priority Date Filing Date
CN 200410060534 Expired - Fee Related CN1261149C (en) 2004-09-23 2004-09-23 Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis

Country Status (1)

Country Link
CN (1) CN1261149C (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101015682B (en) * 2007-02-01 2011-02-02 兰州奇正健康日用品有限公司 Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof
CN102441154A (en) * 2011-11-23 2012-05-09 朱法存 Chinese medicinal preparation for treating gout
CN103919965A (en) * 2014-04-30 2014-07-16 蚌埠明日欣医药有限公司 Traditional Chinese medicine mixture for treating ankylosing spondylitis
CN105920264A (en) * 2016-04-27 2016-09-07 石良 Ankylosing spondylitis rehabilitation pill as well as preparation method and taking method thereof
CN106039223A (en) * 2016-07-14 2016-10-26 路杨景 Traditional Chinese medicine composition for treating arthropathy and manufacturing method of Traditional Chinese medicine composition pills
WO2018228431A1 (en) * 2017-06-13 2018-12-20 首都医科大学附属北京地坛医院 Use of cimicifugae foetidae triterpenoid saponin extract, actein and deoxyactein

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101015682B (en) * 2007-02-01 2011-02-02 兰州奇正健康日用品有限公司 Medicine composition with compact bone substance density improving function, preparing process and quality controlling means thereof
CN102441154A (en) * 2011-11-23 2012-05-09 朱法存 Chinese medicinal preparation for treating gout
CN103919965A (en) * 2014-04-30 2014-07-16 蚌埠明日欣医药有限公司 Traditional Chinese medicine mixture for treating ankylosing spondylitis
CN105920264A (en) * 2016-04-27 2016-09-07 石良 Ankylosing spondylitis rehabilitation pill as well as preparation method and taking method thereof
CN106039223A (en) * 2016-07-14 2016-10-26 路杨景 Traditional Chinese medicine composition for treating arthropathy and manufacturing method of Traditional Chinese medicine composition pills
WO2018228431A1 (en) * 2017-06-13 2018-12-20 首都医科大学附属北京地坛医院 Use of cimicifugae foetidae triterpenoid saponin extract, actein and deoxyactein
US11052099B2 (en) 2017-06-13 2021-07-06 Beijing Ditan Hospital, Capital Medical University Use of cimicifugae rhizoma triterpenoid saponin extract, actein, and deoxyactein

Also Published As

Publication number Publication date
CN1261149C (en) 2006-06-28

Similar Documents

Publication Publication Date Title
CN101028481A (en) Medicinal liquor for treating hyperosteogency and koilorrhachic
CN101161273A (en) A Chinese patent medicine for treating catagmat
CN1634311A (en) Medicine for treating rheumatoid arthritis, femur necrosis and ankylosing spondylitis
CN1261139C (en) Medicine for treating bone tuberculosis, osteomyelitis, synovitis and angeitis
CN1698735A (en) Medicine for treating psoriasis
CN1539441A (en) Compounded medicine for anti pathogeny and immunoenhancement
CN1201691A (en) Medicine for curing encephalatrophy and preparation thereof
CN1245173C (en) Medicine composition for treating liver fibrillation and liver cirrhosis and its prepn process
CN1317315A (en) Tendon-comfortable analgesic
CN1386546A (en) Capsule 'Yibao Yishou' for elongating life
CN1698863A (en) Chinese medicine preparation for treating hyperosteogeny
CN1478509A (en) Health-care liquid
CN1141114C (en) Tendon-conditioning analgetic
CN1136899C (en) Chinese medicine for treating mastoplasia
CN1167433C (en) Medicine for treating acne and its preparing process
CN1161135C (en) Medicine for curing carcinoma of stomach
CN1199685C (en) Medicine for treating upper respiratory tract infection type cold
CN1036503C (en) Medicine for treating systemic lupus erythematosus and producing method thereof
CN107753700A (en) A kind of medicine for treating chronic hepatitis
CN1176108A (en) Kidney-warming and Yang-activating medicine
CN1272060C (en) Medicine for preventing apoplexy and its preparation method
CN1156292C (en) Medicine for curing cholecystitis and its preparing method
CN1872255A (en) Oral liquid for apoplexia
CN1907396A (en) Medicine for treating cerebral hemorrhage
CN1150015C (en) Medicine for treating leucocytopenia caused by lupus erythematosus

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee